Cooley advised AN2 Therapeutics, Inc., and Davis Polk & Wardwell advised the joint book-running managers on the offering.AN2 Therapeutics, Inc. (Nasdaq:ANTX) announced a SEC-registered follow-on offering…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
